Viz

Viz.ai Receives First De Novo Approval by the FDA for Hypertrophic Cardiomyopathy AI Algorithm

Retrieved on: 
Tuesday, August 15, 2023
Software, Apps, Applications, Medical Devices, Technology, Hospitals, Artificial Intelligence, Health Technology, Surgery, Cardiology, Nursing, FDA, Health, De novo, Prevalence, ECG, Intelligence, Bristol Myers Squibb, BMY, Viz, Hospital, Platform, MD, Hypertrophic cardiomyopathy, Patient, Algorithm, Artificial intelligence, Diagnosis, AI, Atlantic Health System, Automated ECG interpretation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HCM, NYSE, Food, Medical device

The deployment of the algorithm is financially supported by a multi-year agreement with Bristol Myers Squibb (NYSE: BMY) announced in March.

Key Points: 
  • The deployment of the algorithm is financially supported by a multi-year agreement with Bristol Myers Squibb (NYSE: BMY) announced in March.
  • With the use of Viz HCM, which is integrated into the Viz.ai Platform, more patients with suspected HCM can be identified earlier using AI and triaged for diagnosis and further evaluation.
  • “Hypertrophic cardiomyopathy is a devastating disease that is often undetected until it is too late.
  • “We are thrilled with this De Novo approval, which establishes the new FDA category of cardiovascular machine learning-based notification software.

Three New Clinical Studies Presented at the Society of Neurointerventional Surgery Annual Meeting Further Validate Impact of Viz™ Neuro Suite

Retrieved on: 
Monday, July 31, 2023
Mental Health, Surgery, Infectious Diseases, Veterans, Hospitals, Genetics, Fitness & Nutrition, Dental, Clinical Trials, Cardiology, Software, Biotechnology, Alternative Medicine, AIDS, Health, Technology, Nursing, Medical Supplies, FDA, Diabetes, Stem Cells, Practice Management, Physical Therapy, Managed Care, Defense, Other Health, Radiology, Pharmaceutical, Optical, Artificial Intelligence, Oncology, Stroke, Abstract, Communication, CT, Society, University, Interventional neuroradiology, Disease, The Valley Hospital, Health equity, Digital subtraction angiography, Risk, CNS, Viz, Ambient occlusion, Community hospital, Triage, Patient, Algorithm, AI, Incidence, Medical imaging

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the presentation of three new abstracts that demonstrate the real-world impact of the Viz Neuro Suite at the Society of Neurointerventional Surgery (SNIS) Annual Meeting.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the presentation of three new abstracts that demonstrate the real-world impact of the Viz Neuro Suite at the Society of Neurointerventional Surgery (SNIS) Annual Meeting.
  • These independent studies demonstrate the clinical, health equity, and patient benefits of AI-driven technology, and reiterate Viz.ai’s commitment to transforming patient care.
  • The findings underscore the critical role of Viz.ai's advanced AI algorithms in accurately identifying and triaging patients for prompt intervention, ultimately improving outcomes and saving lives.
  • "The Viz.ai platform has become an invaluable tool in our practice, and I rely on it when I’m on call."

Viz.ai Appoints Hypertrophic Cardiomyopathy Medical Advisory Board to Advance Innovation

Retrieved on: 
Thursday, May 4, 2023
Health, Medical Devices, Technology, Health Technology, Other Health, Software, Artificial Intelligence, File, Hypertrophic cardiomyopathy, Intelligence, Sports cardiology, Research, Cardiology, De novo, Sale, Science, Viz, UCSF, Artificial intelligence, AI, Atlantic Health System, FDA, HCM, Nursing, Pharmaceutical industry, Medical device, MD

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the creation of its Hypertrophic Cardiomyopathy (HCM) Medical Advisory Board to assist the company in the development of strategy and products to support cardiologists and improve patient care.

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the creation of its Hypertrophic Cardiomyopathy (HCM) Medical Advisory Board to assist the company in the development of strategy and products to support cardiologists and improve patient care.
  • The board consists of leading cardiology experts with diverse roles and experiences.
  • “The role of artificial intelligence in cardiology is growing exponentially and the creation of the HCM Medical Advisory Board will ensure the Viz.ai’s cardiovascular program will be shaped with the latest insights in the field,” said Matthew Martinez, MD, Director of Sports Cardiology and HCM, Atlantic Health System, and co-chair of the HCM Medical Advisory Board.
  • “Working alongside other HCM experts with clinical experience using artificial intelligence, I’m eager to contribute to innovative developments that will improve patient outcomes.”
    “I’m honored to share my expertise to enhance Viz.ai’s approach toward innovation,” said Roselle Abraham, MD, Director of the Hypertrophic Cardiomyopathy Clinic and Cardiologist, UCSF and co-chair of the HCM Medical Advisory Board.

Viz.ai is First to Receive FDA 510(k) Clearance for AI Algorithm for Abdominal Aortic Aneurysm

Retrieved on: 
Tuesday, March 21, 2023
Technology, Medical Devices, Health Technology, Cardiology, Software, Biotechnology, Health, General Health, Artificial Intelligence, Heart, Communication, Abdominal aortic aneurysm, Pulmonary embolism, AAA1, Food and Drug Administration, Aortic rupture, Intelligence, CTA, Multimedia, Risk, TriHealth, Viz, Death, Hospital, Triage, Rupture, AAA, MD, Patient, Physician, Blood, Korea Disease Control and Prevention Agency, Artificial intelligence, AI, FDA, Computed tomography angiography, Food, Disease, Medical device, Medical imaging

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its algorithm intended to detect suspected abdominal aortic aneurysm (AAA).

Key Points: 
  • Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its algorithm intended to detect suspected abdominal aortic aneurysm (AAA).
  • The new artificial intelligence (AI) algorithm and clinical workflow solution will be a part of the VizTM AORTIC Module, an AI solution designed to accelerate treatment decisions for all aortic pathology.
  • An abdominal aortic aneurysm is a bulge in the abdominal aorta, the main artery that carries blood from the heart to the rest of the body.
  • Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals.

Viz.ai to Expedite Patient Enrollment in NIH-funded PE-TRACT Clinical Trial

Retrieved on: 
Saturday, March 4, 2023
Surgery, Medical Devices, Clinical Trials, Health Technology, Cardiology, Practice Management, Biotechnology, Biometrics, Health, Pulmonary embolism, National Heart, Lung, and Blood Institute, Patient, Viz, AI, Faculty, Clinical trial, Workflow, Anticoagulant, Lung, Thrombolysis, Interventional radiology, Weill Cornell Medicine, Bangladesh Technical Education Board, Research, Triage, Medical imaging, Pharmaceutical industry

The PE-TRACT trial will be the most rigorous randomized controlled clinical trial to date of catheter-directed therapy for pulmonary embolism, with plans to enroll 500 patients across 30-50 sites.

Key Points: 
  • The PE-TRACT trial will be the most rigorous randomized controlled clinical trial to date of catheter-directed therapy for pulmonary embolism, with plans to enroll 500 patients across 30-50 sites.
  • Viz.ai’s RECRUIT tool has the potential to efficiently identify potential participants and help this important trial complete enrollment on time.”
    Participating research institutions in the PE-TRACT trial will use Viz RECRUIT to find, screen, and enroll clinical trial candidates.
  • “We’re honored to be the partner of choice for this clinical trial to accelerate vascular research using Viz RECRUIT.
  • With our platform’s real-world accuracy and demonstrated success, researchers can use AI to identify potentially eligible trial candidates, regardless of their location, ultimately expediting the clinical trial enrollment process,” said Jayme Strauss, chief clinical officer, Viz.ai.

Large Real-World, Multi-Center Study Demonstrates Viz.ai Platform Saves Critical Minutes in Stroke Care

Retrieved on: 
Wednesday, February 8, 2023
Health, Technology, Hospitals, Health Technology, Software, Artificial Intelligence, Validation, Artificial intelligence, DO, Artificiality, Neurology, Hospital, Treatment, Neuron, Telehealth, Patient, Stroke, ISC, Multimedia, Conference, Viz, AI, Medical device

The study demonstrated that hospital utilization of Viz’ AI-powered care coordination platform was associated with a 39.5 minute reduction in patient arrival to time of first contact with the neurointerventionalist for need for potential emergency endovascular treatment.

Key Points: 
  • The study demonstrated that hospital utilization of Viz’ AI-powered care coordination platform was associated with a 39.5 minute reduction in patient arrival to time of first contact with the neurointerventionalist for need for potential emergency endovascular treatment.
  • A total of 14,116 patients were included from two groups: those seen in hospitals using AI (n=8,557) and those seen in hospitals not using AI (n=5,559).
  • The study found that the median door to neurointerventionalist notification time for AI was 50 minutes compared to the median door to neurointerventionalist notification time for non-AI at 89.5 minutes (p
  • For more information on the study results, visit the ISC website .

Viz.ai Launches AI-Powered Viz™ Vascular Suite

Retrieved on: 
Thursday, January 12, 2023
Health, Technology, Hospitals, Health Technology, Software, Artificial Intelligence, Cardiology, AAA, Communication, Pathology, Pulmonary embolism, FDA, MD, AI, CT, ECG, Viz, Patient, Intelligence, Degenerative disease, Multimedia, Health, Triage, Medical device, Medical imaging

View the full release here: https://www.businesswire.com/news/home/20230112005812/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230112005812/en/
    “Recognizing the symptoms of serious vascular conditions, such as aortic dissections, is hugely important because any delay in treatment can have a direct impact on patient outcomes,” said Philip Batista, MD, Associate Program Director, Vascular and Endovascular Surgery Residency, Cooper.
  • We’ve been using the Viz software for the last several months and have seen improvements in patient care across our institution.”
    The Viz Vascular Suite uses artificial intelligence to automatically analyze an array of imaging modalities, including computerized tomography (CT), electrocardiogram (ECG), and more for suspected vascular diseases.
  • Clinicians can use Viz Vascular Suite to remotely coordinate vascular pathology care within a hospital system’s hub and spoke network and enable synchronous, HIPAA-compliant communication among specialists.
  • The Viz Vascular Suite will bring the advantages of intelligent care coordination to even more patients and help clinical teams achieve better clinical outcomes,” said Chris Mansi, CEO of Viz.ai.

5 Rug Trends Interior Designers Expect to See In 2023

Retrieved on: 
Tuesday, December 20, 2022
WINCHESTER, Organic, Environment, Wool, Interior, BY, Multimedia, Viz, Carpet

WINCHESTER, Va., Dec. 20, 2022 /PRNewswire/ -- From the rise of geometrically patterned rugs to trends inspired by middle eastern designs, Rugs Direct asked interior designers to share their thoughts on what trends we can expect to see emerge in 2023.

Key Points: 
  • WINCHESTER, Va., Dec. 20, 2022 /PRNewswire/ -- From the rise of geometrically patterned rugs to trends inspired by middle eastern designs, Rugs Direct asked interior designers to share their thoughts on what trends we can expect to see emerge in 2023.
  • Rugs Direct asked interior designers to share their thoughts on what trends we can expect to see emerge in 2023.
  • Outdoor rugs: "The whole indoor/outdoor rug industry is going to take it to a new level in 2023," shares interior designer Jen Dallas .
  • Organic rugs:  "We will continue to be eco-conscious in 2023, which means a focus on natural materials and vintage rugs," shares interior designer Beth Martin.

Viz.ai Appoints Radiology Advisory Board to Advance Innovation

Retrieved on: 
Monday, November 28, 2022
Biotechnology, Technology, Health, General Health, Radiology, Pharmaceutical, Health Technology, Medical Devices, Software, Artificial Intelligence, Hospitals, Science, Diagnosis, Neuroradiology, AI, Machine learning, Hospital, Patient, Radiology, Disease, MD, Baptist Hospital, MRI, Chairperson, Medical director, Viz, Research, Intelligence, Algorithm, Medical imaging, Medical device

The Board consists of 14 leading healthcare experts with diverse experience and roles in radiology.

Key Points: 
  • The Board consists of 14 leading healthcare experts with diverse experience and roles in radiology.
  • I am honored to co-chair the Radiology Advisory Board and excited about Viz.ais commitment to customers and patients to invest in innovation that increases access to life-saving therapies, said Kevin Abrams, MD, medical director of neuroradiology and MRI and chief of radiology at Baptist Hospital in Miami.
  • Im looking forward to working with these esteemed board members to help shape Viz.ais Radiology Program through patient-centric vision, passion, and insights, said Suzie Bash, MD, Co-Chair of the Viz.ai Radiology Advisory Board and Medical Director of Neuroradiology at San Fernando Valley Interventional Radiology at RADNET.
  • The Board will assist the Viz team in informing its radiology strategy and research and development activities.

Viz.ai™ Announces Positive New Data From Large Aortic Dissection AI Real-World Study at the 2022 VEITHsymposium™

Retrieved on: 
Friday, November 18, 2022
Health, Technology, Health Technology, Software, Radiology, Artificial Intelligence, Cardiology, Hospital, Communication, Workflow, AI, UC, Algorithm, University of California, Irvine, Patient, Machine learning, Deep learning, CINA, Triage, Disease, Mortality, Artificial intelligence, Radiology, CT, City, Assistant, Diagnosis, Risk, Viz, Medical diagnosis, Blood vessel, Health, Medical device

Data from the new study, which was presented this week at the 2022 VEITHSymposium, validates the companys industry-leading dissection detection algorithm, part of the Viz AORTIC solution.

Key Points: 
  • Data from the new study, which was presented this week at the 2022 VEITHSymposium, validates the companys industry-leading dissection detection algorithm, part of the Viz AORTIC solution.
  • The authors concluded, These findings provide significant real-world validation of a deep-learning AI-based detection algorithm for suspected aortic dissection.
  • Acute aortic dissection is a deadly disease, and mortality for an untreated dissection is about 50% by 24 hours.
  • For more information on the study results and Viz Aortic, please join a webinar on Wednesday, November 30th at 5pm ET.